As per the terms of the agreement, GSK is responsible to pay up to EUR5.5m to MolMed in revenues for a term of two-year.
Developed by the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), the gene therapy is in late stage clinical trials and was in-licensed by GSK to develop and commercialize the therapy.
MolMed chairman and CEO Claudio Bordignon said the company has expertise and know-how in the field of gene and cell therapy and this agreement with GSK is an important step on the way to provide gene therapy for patients with rare diseases.